Is Europe a Value Trap or a Buying Opportunity?

European stocks remain plagued by high political uncertainty and economic problems leading to successive downgrades of growth expectations for the region

Clémence Dachicourt 20 February, 2019 | 8:22AM
Facebook Twitter LinkedIn

Louvre Paris France are European equities undervalued stock picking

European equities have consistently underperformed global equities – this holds true over 10, five, three or even one year. They continued to lag during last’s month rally so you could categorise them as a value trap.

Having said this, a lot of negativity seems to be priced into the asset class which has suffered from massive outflows. This has resulted in current exposure levels that are only slightly higher than those seen during the Eurozone crisis. 

European stocks remain plagued by high political uncertainty and economic problems leading to successive downgrades of growth expectations for the region, the latest one by the IMF in October 2018 over concerns of the slowdown of Europe’s growth engine: Germany.

From a contrarian standpoint, one could nevertheless argue that this growth scare led to European equities being overly discounted. Most investors expect a deterioration of European profits within the next twelve months.

This doesn’t mean that profits don’t have the potential to come down, however the second derivative of revisions might well be positive. The lower number of profit warnings so far this earnings season compared to Q3 could be an indication that things are finally improving.

Someone with a long-term mindset and the ability to absorb some volatility could see opportunities in the more cyclical sectors. European banks currently trade on 0.8 times price to book value. This is a bit higher than where the sector was trading during the Eurozone crisis, but betrays little evidence of all the measures put in place by the ECB to revive the sector’s profitability which are finally bearing fruit.

European telecoms and energy also caught our attention, yet one might want to pair them with less operational or financial geared sectors such as European healthcare. Despite its recent uptick, pharmaceuticals continue to show good value thanks to strong FCF generation and attractive dividend yields.

A version of this article appeared in Investment Week magazine

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Clémence Dachicourt  is Senior Portfolio Manager for Morningstar Investment Management

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures